RT Journal Article
SR Electronic
T1 CAR-T cells Targeting Thyroid-stimulating Hormone Receptor (TSHR) Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.15.21256466
DO 10.1101/2021.05.15.21256466
A1 Hanning Li
A1 Xiang Zhou
A1 Ge Wang
A1 Dongyu Hua
A1 Shuyu Li
A1 Tao Xu
A1 Menglu Dong
A1 Xiaoqing Cui
A1 Xue Yang
A1 Yonglin Wu
A1 Miaomiao Cai
A1 Xinghua Liao
A1 Tongcun Zhang
A1 Zhifang Yang
A1 Yaying Du
A1 Xingrui Li
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.15.21256466.abstract
AB Background Differentiated thyroid cancer (DTC) is usually very treatable and is often cured with surgery and, if indicated, follow with radioactive iodine (RAI) and long-term thyroid-stimulating hormone (TSH) suppression with levothyroxine. Unfortunately, locoregional relapse and distant metastases occur in up to 20% at ten years; those relapsed or distant metastatic thyroid cancer is relatively uncommon compare to other cancers, cytotoxic chemotherapies provided low response rates, and two-thirds of cases became RAI refractory (RAI-R). New therapy options for local-regional relapsed or distant metastases thyroid cancer are desperately needed. Chimeric antigen receptor T cells (CAR-T) have been demonstrated remarkable efficacy in hematological cancers but have not yet translated in treating solid tumors. The significant hurdles limiting CAR-T therapy were due to a paucity of differentially expressed cell surface molecules on solid tumors that can be safely targeted. Here, we present thyroid-stimulating hormone receptor (TSHR) as a putative target for CAR-T therapy of DTC.Methods We undertook a large-scale screen on thyroid cancer tissues and multiple internal organs through bioinformatical analysis and immunohistochemistry to date TSHR expression. Using three previously described mAb, we generate three third-generation CAR-Ts. We tested anti-TSHR CAR-T in vitro activity by T-cell function assay and killing assay. Then we tested pre-clinical therapeutical efficacy in a xenograft mouse model of DTC and analyzed mice’s physical conditions and histological abnormalities to evaluate anti-TSHR CAR-T’s safety.Results TSHR is highly and homogeneously expressed on 90.8%(138/152) of papillary thyroid cancer, 89.2% (33/37) of follicular thyroid cancer, 78.2% (18/23) of the cervical lymph node metastases, and 86.7% of locally recurrent or metastasis lesions with RAI-R disease. We develop three novel anti-TSHR CAR-T from mAb M22, K1-18, and K1-70, all three CAR-Ts mediate significant anti-tumor activity in vitro. Among these, we demonstrate that K1-70 CAR-T can have therapeutical efficacy in vivo, and no apparent toxicity has been observed.Conclusion TSHR is a latent target antigen of CAR-T therapy for DTC. Anti-TSHR CAR-T has strong therapeutical efficacy in vivo while without prominent adverse events. Anti-TSHR CAR-T could represent an exciting therapeutic option for patients with specific local-regional relapsed or distant metastases thyroid cancer and should be tested in carefully designed clinical trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank all members of the Thyroid and Breast surgery laboratory and various colleagues in the Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.YD is supported by the National Natural Science Foundation of China (No.81802676). XL is supported Wuhan Youth Cadre Project (2017zqnlxr01 and 2017zqnlxr02), Clinical Research Physician Program of Tongji Medical College, HUST(5001540018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human sample work was performed under the guidelines of the Medical Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Institution Review Board Approval: TJ-C20180110). Each patient involved in the study was asked to sign a written informed consent form and the specimens were anonymized and handled according to accepted ethical and legal standards. All animal work was approved by Huazhong University of Science and Technology’s Institutional Animal Care and Use Committee and performed with approved protocols (#2018-0110).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this article and its supplementary information files.